Founded in 2016 and headquartered in Jerusalem, Israel, Alpha Tau Medical focuses on addressing high unmet needs in oncology through its localized radiation therapy. The company's flagship Alpha DaRT technology utilizes the decay chain of Radium-224 to release short-lived alpha-emitting atoms that destroy tumor cells by causing irreparable DNA breaks. Alpha Tau is conducting multiple clinical trials globally, including pivotal and pilot studies for recurrent cutaneous squamous cell carcinoma (cSCC), pancreatic cancer, and glioblastoma multiforme (GBM). The Alpha DaRT device has received Breakthrough Device Designation from the U.S. FDA and marketing approval in Japan. The company operates primarily in Israel, the United States, and Japan, collaborating with leading medical institutions to expand its clinical pipeline.
